Zosuquidar: Difference between revisions

Jump to navigation Jump to search
m (Protected "Zosuquidar": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)))
 
m (Robot: Automated text replacement (-{{SIB}} +, -{{EH}} +, -{{EJ}} +, -{{Editor Help}} +, -{{Editor Join}} +))
 
Line 27: Line 27:
}}
}}
{{SI}}
{{SI}}
{{EH}}
 


==Overview==
==Overview==
Line 39: Line 39:
[[Category:Chemotherapeutic agents]]
[[Category:Chemotherapeutic agents]]
[[Category:Organofluorides]]
[[Category:Organofluorides]]
{{SIB}}
 


[[ja:Zosuquidar]]
[[ja:Zosuquidar]]
{{WikiDoc Help Menu}}
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}
{{WikiDoc Sources}}

Latest revision as of 17:35, 20 August 2012

Zosuquidar
File:Zosuquidar.svg
Identifiers
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC32H31F2N3O2
Molar mass527.61 g/mol
3D model (JSmol)

WikiDoc Resources for Zosuquidar

Articles

Most recent articles on Zosuquidar

Most cited articles on Zosuquidar

Review articles on Zosuquidar

Articles on Zosuquidar in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Zosuquidar

Images of Zosuquidar

Photos of Zosuquidar

Podcasts & MP3s on Zosuquidar

Videos on Zosuquidar

Evidence Based Medicine

Cochrane Collaboration on Zosuquidar

Bandolier on Zosuquidar

TRIP on Zosuquidar

Clinical Trials

Ongoing Trials on Zosuquidar at Clinical Trials.gov

Trial results on Zosuquidar

Clinical Trials on Zosuquidar at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Zosuquidar

NICE Guidance on Zosuquidar

NHS PRODIGY Guidance

FDA on Zosuquidar

CDC on Zosuquidar

Books

Books on Zosuquidar

News

Zosuquidar in the news

Be alerted to news on Zosuquidar

News trends on Zosuquidar

Commentary

Blogs on Zosuquidar

Definitions

Definitions of Zosuquidar

Patient Resources / Community

Patient resources on Zosuquidar

Discussion groups on Zosuquidar

Patient Handouts on Zosuquidar

Directions to Hospitals Treating Zosuquidar

Risk calculators and risk factors for Zosuquidar

Healthcare Provider Resources

Symptoms of Zosuquidar

Causes & Risk Factors for Zosuquidar

Diagnostic studies for Zosuquidar

Treatment of Zosuquidar

Continuing Medical Education (CME)

CME Programs on Zosuquidar

International

Zosuquidar en Espanol

Zosuquidar en Francais

Business

Zosuquidar in the Marketplace

Patents on Zosuquidar

Experimental / Informatics

List of terms related to Zosuquidar


Overview

Zosuquidar is a compound of antineoplastic drug candidates currently under development. It is now in "Phase 3" of clinical tests in the United States. Its action mechanism consists of the inhibition of P-glycoproteins; other drugs with this mechanism include tariquidar and laniquidar. P-glycoproteins are proteins which convert the energy derived from the hydrolysis of ATP to structural changes in protein molecules, in order to perform coupling, thus discharging medicine from cells. If P-glycoprotein coded with the MDR1 gene manifests itself in cancer cells, it discharges much of the antineoplastic drugs from the cells, making cancer cells medicine tolerant, and rendering antineoplastic drugs ineffective. This protein also manifests itself in normal organs not affected by the cancer (such as the liver, small intestine, and skin cells in blood vessels of the brain), and participates in the transportation of medicine. The compound Zosuquidar inhibits this P-glycoprotein, causing the cancer cells to lose their medicine tolerance, and making antineoplastic drugs effective.

References


Template:WikiDoc Sources